Circulating microRNA changes to predict neoadjuvant chemotherapy response in breast cancer.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, single-center observational project enrolls adults with histologically confirmed breast cancer who are scheduled to receive standard neoadjuvant chemotherapy. Serum samples are collected before starting chemotherapy and again after completing chemotherapy but before surgery, and selected circulating microRNAs (including the miR-200 family, miR-34a, miR-221/222, miR-155, and miR-146a) are measured by quantitative RT-PCR. Pathological response is determined using pathological complete response (pCR) status and Miller-Payne tumor regression grading at surgery, and analyses will examine associations between miRNA dynamics, breast cancer subtypes, and circulating tumor cell levels. No investigational drugs or devices are used and all treatments follow routine clinical care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed breast cancer
* Planned to receive neoadjuvant chemotherapy
* Biologically female
* Age ≥ 18 years
* Ability to provide informed consent
* Adequate organ function to receive standard NAC (based on routine clinical evaluation)

Exclusion Criteria:

* Presence of metastatic disease at diagnosis
* Prior systemic chemotherapy for breast cancer
* Pregnancy or breastfeeding
* Active infection or uncontrolled comorbid conditions interfering with study participation
* Any condition preventing collection of blood samples

Where it's running

• Istanbul Atlas University Faculty of Medicine
  Istanbul, Turkey (Türkiye) Recruiting

Study contacts

• Principal investigator: Emine Yildirim, MD — Atlas University Faculty of Medicine
• Study coordinator: Emine Yildirim, MD
• Email: opdreyildirim@gmail.com
• Phone: +905056234825

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neoadjuvant therapy for early triple-negative breast cancer using QL1706 plus chemotherapy guided by response

  This study tests if adding QL1706 (a PD-1/CTLA-4 blocker) to chemotherapy before surgery can shrink early triple-negative breast tumors and spare some patients from anthracyclines.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07372079

• Reducing sitting time and increasing daily activity during cancer treatment

  This project will try a digital self-management program plus physiotherapist support to help people with breast, prostate, or colorectal cancer who are starting neo- or adjuvant treatment sit less and feel better during and after treatment.

  Recruiting at 2 sites Mälardalen University · Uppsala and 1 other locations · NCT06719206

• Skipping axillary surgery when lymph nodes look normal on ultrasound after preoperative chemotherapy

  This trial tests whether skipping axillary lymph node surgery after neoadjuvant chemotherapy is safe for breast cancer patients whose lymph nodes look normal on ultrasound.

  Recruiting Phase 3 Seoul National University Hospital · Seoul · NCT06704945

• Less invasive axillary treatment for breast cancer after chemotherapy

  This study tests if a less invasive way to treat breast cancer after chemotherapy can keep women safe and improve their quality of life compared to more invasive methods.

  Recruiting at 35 sites Maastricht University Medical Center · 's-Hertogenbosch and 34 other locations · NCT04486495

• Gyrotonic exercise for elders with breast cancer and Behcet disease

  We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.

  Recruiting Cairo University · Giza, Dokki · NCT07929116

• PECS II vs SPSIP nerve blocks for pain after mastectomy

  This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.

  Recruiting Bursa City Hospital · Nilufer, Bursa · NCT07929090

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.